Free Trial

Alnylam Pharmaceuticals (ALNY) News Today

$240.02
-9.81 (-3.93%)
(As of 05:38 PM ET)
Alnylam Pharmaceuticals logo with Medical background
Headlands Technologies LLC Purchases New Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Headlands Technologies LLC bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 3,150 shares of the biopharmaceutical company's stock, valued at a
3 Biopharma Stocks to Buy for Long-Term Growth
Alnylam Pharmaceuticals logo with Medical background
Forsta AP Fonden Increases Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Forsta AP Fonden grew its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 199.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 68,300 shares of the biopharmaceutical comp
Alnylam Pharmaceuticals logo with Medical background
Susquehanna Fundamental Investments LLC Acquires Shares of 88,067 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Susquehanna Fundamental Investments LLC acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 88,067 shares of the biopharmaceutical company's stock, valued at approximately $13,1
Alnylam Pharmaceuticals logo with Medical background
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Consensus Rating of "Moderate Buy" from Brokerages
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the twenty-four analysts that are currently covering the company, Marketbeat reports. Eight research analysts have rated the stock with a hold recommendation a
Alnylam Pharmaceuticals logo with Medical background
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Sells $1,851,273.00 in Stock
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) CEO Yvonne Greenstreet sold 7,093 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $261.00, for a total transaction of $1,851,273.00. Following the sale, the chief executive officer now directly owns 73,441 shares in the company, valued at approximately $19,168,101. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Alnylam Pharmaceuticals logo with Medical background
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Lessened by Duality Advisers LP
Duality Advisers LP trimmed its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 34.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,197 shares of th
Alnylam Pharmaceuticals logo with Medical background
Morgan Stanley Boosts Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $255.00
Morgan Stanley boosted their price objective on Alnylam Pharmaceuticals from $250.00 to $255.00 and gave the stock an "equal weight" rating in a report on Friday.
Alnylam Pharmaceuticals logo with Medical background
Short Interest in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Grows By 72.8%
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) was the target of a large growth in short interest in June. As of June 30th, there was short interest totalling 3,680,000 shares, a growth of 72.8% from the June 15th total of 2,130,000 shares. Based on an average daily volume of 939,700 shares, the days-to-cover ratio is currently 3.9 days.
Alnylam Pharmaceuticals logo with Medical background
Mediolanum International Funds Ltd Invests $5.95 Million in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Mediolanum International Funds Ltd acquired a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 38,556 shares of the biopharmaceutical company's stock, valued at approximate
Alnylam Pharmaceuticals logo with Medical background
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock Holdings Increased by Mirae Asset Global Investments Co. Ltd.
Mirae Asset Global Investments Co. Ltd. lifted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 63.4% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 62,415 shares of the biop
Alnylam Pharmaceuticals logo with Medical background
Alnylam Pharmaceuticals (NASDAQ:ALNY) Reaches New 52-Week High After Analyst Upgrade
Alnylam Pharmaceuticals (NASDAQ:ALNY) Hits New 12-Month High After Analyst Upgrade
Alnylam Pharmaceuticals logo with Medical background
Tobam Has $10.32 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Tobam trimmed its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 24.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 69,062 shares of the biopharmaceutical company's stock after selling 21,979 sh
Alnylam Pharmaceuticals logo with Medical background
Van ECK Associates Corp Cuts Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Van ECK Associates Corp cut its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 5.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 57,923 shares of the biopharmaceutical com
Alnylam Pharmaceuticals logo with Medical background
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $248.00
JPMorgan Chase & Co. raised their price objective on Alnylam Pharmaceuticals from $160.00 to $248.00 and gave the company a "neutral" rating in a research note on Wednesday.
Alnylam Pharmaceuticals logo with Medical background
Quattro Financial Advisors LLC Grows Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Quattro Financial Advisors LLC increased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 2,517.8% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,000 shares of the biopharmaceutical compa
Alnylam Pharmaceuticals logo with Medical background
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by SteelPeak Wealth LLC
SteelPeak Wealth LLC increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 147.7% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 6,860 shares of the biopharmaceutical company's st
Alnylam Pharmaceuticals logo with Medical background
Zacks Research Brokers Decrease Earnings Estimates for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) - Research analysts at Zacks Research decreased their Q1 2025 earnings estimates for shares of Alnylam Pharmaceuticals in a research note issued on Wednesday, June 26th. Zacks Research analyst A. Chakraborty now forecasts that the biopharm
Alnylam Pharmaceuticals logo with Medical background
UBS Group Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $288.00
UBS Group upped their target price on Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the company a "buy" rating in a research report on Friday.
Alnylam Pharmaceuticals logo with Medical background
Alnylam Pharmaceuticals, Inc. Expected to Earn Q2 2024 Earnings of ($0.90) Per Share (NASDAQ:ALNY)
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) - Equities research analysts at Leerink Partnrs raised their Q2 2024 EPS estimates for shares of Alnylam Pharmaceuticals in a research note issued to investors on Tuesday, June 25th. Leerink Partnrs analyst M. Foroohar now expects that the
Alnylam Pharmaceuticals logo with Medical background
Alnylam Pharmaceuticals (NASDAQ:ALNY) PT Raised to $295.00 at Stifel Nicolaus
Stifel Nicolaus lifted their target price on shares of Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the company a "buy" rating in a report on Thursday.
Alnylam Pharmaceuticals logo with Medical background
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Los Angeles Capital Management LLC
Los Angeles Capital Management LLC lowered its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 82.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,959 shares of the biopharmaceutical company's
Alnylam Pharmaceuticals logo with Medical background
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $291.00 at Citigroup
Citigroup increased their price objective on shares of Alnylam Pharmaceuticals from $227.00 to $291.00 and gave the stock a "buy" rating in a research note on Tuesday.
Alnylam Pharmaceuticals logo with Medical background
Alnylam Pharmaceuticals (NASDAQ:ALNY) Sees Strong Trading Volume on Analyst Upgrade
Alnylam Pharmaceuticals (NASDAQ:ALNY) Sees Large Volume Increase on Analyst Upgrade
RNAi: Winning In The Clinic, Now For The Market
Alnylam Pharmaceuticals logo with Medical background
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $275.00
Needham & Company LLC upped their target price on Alnylam Pharmaceuticals from $200.00 to $275.00 and gave the stock a "buy" rating in a research report on Monday.
Alnylam Pharmaceuticals logo with Medical background
BMO Capital Markets Reaffirms "Outperform" Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)
BMO Capital Markets reaffirmed an "outperform" rating and issued a $234.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday.
Alnylam Pharmaceuticals logo with Medical background
Alnylam Pharmaceuticals (NASDAQ:ALNY) Hits New 52-Week High at $231.00
Alnylam Pharmaceuticals (NASDAQ:ALNY) Sets New 52-Week High at $231.00
Alnylam Pharmaceuticals logo with Medical background
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Cut by First Hawaiian Bank
First Hawaiian Bank lessened its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 96.4% in the first quarter, according to its most recent filing with the SEC. The firm owned 4,000 shares of the biopharmaceutical company's stock after selling 106,000 shares during
Alnylam Pharmaceuticals logo with Medical background
Alnylam Pharmaceuticals (NASDAQ:ALNY) Earns "Buy" Rating from Canaccord Genuity Group
Canaccord Genuity Group reiterated a "buy" rating and issued a $283.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday.
Alnylam Pharmaceuticals logo with Medical background
Alnylam Pharmaceuticals (NASDAQ:ALNY) Trading 4.1% Higher
Alnylam Pharmaceuticals (NASDAQ:ALNY) Trading 4.1% Higher
Alnylam Pharmaceuticals logo with Medical background
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Goldman Sachs Group Inc.
Goldman Sachs Group Inc. lowered its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 6.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 291,368 shares of th
Alnylam Pharmaceuticals logo with Medical background
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Rating of "Moderate Buy" from Brokerages
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) has been given an average recommendation of "Moderate Buy" by the seventeen ratings firms that are currently covering the company, Marketbeat.com reports. Seven equities research analysts have rated the stock with a hold recommendation a
Get Alnylam Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter.

This company could save the world (Ad)

Many scientists are petrified that AI could wipe humanity out. This isn't a fantasy informed by movies like "Terminator" or "The Matrix." There are legitimate reasons to be afraid of AI.

You can learn more about it here.

ALNY Media Mentions By Week

ALNY Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ALNY
News Sentiment

1.00

0.93

Average
Medical
News Sentiment

ALNY News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ALNY Articles
This Week

21

9

ALNY Articles
Average Week

Get Alnylam Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:ALNY) was last updated on 7/17/2024 by MarketBeat.com Staff

From Our Partners